Family-based Screening and Treatment of Helicobacter Pylori:A Real World Study

Sponsor
Shandong University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04956679
Collaborator
(none)
400
1
10.7
37.3

Study Details

Study Description

Brief Summary

The habit of family meals makes the infection rate of Helicobacter pylori high in China, which is also the main cause of reinfection of Helicobacter pylori. Eating together can easily cause family members to be infected with Helicobacter pylori. We used a real-world study to understand the risk factors, epidemiological characteristics, and safety and effectiveness of eradication therapy for helicobacter pylori infection in family-based screening and treatment.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: carbon 13 breath test

Detailed Description

Helicobacter pylori infection is a worldwide problem, which is the main cause of gastric cancer. The habit of sharing meals in the family is one of the factors contributing to the high infection rate of HP in China, as well as the main cause of reinfection of HP. Sharing meals can easily cause family members to be infected with HP.Family members live together, eat together, share tableware and other behaviors through the "mouth to mouth" transmission of Helicobacter pylori may be infected with each other, is also one of the reasons for the eradication of many patients after re-infection.At the same time, repeated infection and treatment of Helicobacter pylori will increase the difficulty of Helicobacter pylori reeradication.As a family unit, to study the status of our country family helicobacter pylori infection, epidemiological characteristics, infection risk factor, the different schemes, such as the safety and efficacy of treatment to take measures to reduce the infection rate is of great significance to prevention and treatment of gastric cancer.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
400 participants
Observational Model:
Family-Based
Time Perspective:
Prospective
Official Title:
Family-based Screening and Treatment of Helicobacter Pylori:A Real World Study
Actual Study Start Date :
Jul 10, 2021
Anticipated Primary Completion Date :
May 1, 2022
Anticipated Study Completion Date :
Jun 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Family members in the study

Community groups that meet the inclusion criteria

Diagnostic Test: carbon 13 breath test
Patients with positive Helicobacter pylori infection were determined by carbon 13 breath test ,The diagnosis and treatment of positive patients were followed up without other intervention.

Outcome Measures

Primary Outcome Measures

  1. Patient compliance of performing medical examination. [1 year]

    Good compliance of medical examination advice was defined as the subjects took the medical advice given by the doctor and the rate of adoption and implementation of the medical examination advice.

  2. Patient compliance of taking medication [1 year]

    Patient compliance of taking medication is defined as the ratio of the actual dose of medication taken by the patient to the total amount of medication required by the prescription. Good medication compliance is defined as the ratio greater than 80%.

  3. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [1 year]

    Adverse reactions related to medication were recorded

  4. Lesion detection ratio [1 year]

    The lesion detection ratio was defined as the ratio of the number of subjects who underwent medical examination on the basis of doctor's recommendation and were finally diagnosed with lesion to the number of subjects who underwent examination.

  5. Eradication rate [1 year]

    Eradication rate was defined as the ratio of the number of patients diagnosed positive on the carbon 13 breath test to the number of subjects who turned negative after taking the eradication drug to the number of subjects diagnosed positive before taking the drug.

Secondary Outcome Measures

  1. The high-risk factors of Helicobacter pylori infection in families were investigated by questionnaire statistics. [1 year]

    Questionnaire survey was used to conduct information statistics on families undergoing Helicobacter pylori screening.Statistics include family members of the general situation, basic information, personal health and life habit, individual disease history, personal nearly 1 month medications, family health and lifestyle, family history, history of HP infection and the eradication of history, screening results, doctor give opinions and patient adherence and follow-up outcome after screening process, etc. Statistical soft ware was used to analyze factor correlations.

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Community population over 3 years old who signed the informed consent.

  • at least 2 people in the family.

  • living together for at least 10 months each year in the past 5 years except child aged below 5.

Exclusion Criteria:
  • PPI drugs such as esomeprazole、pantoprazole、 rabeprazole,、lansoprazole、famotidine and H2 receptor antagonists were taken within two weeks.

  • antibiotics、bismuth agents or traditional Chinese medicine with antibacterial effect were taken within four weeks

  • There are other factors that researchers think are not suitable for participation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Gastroenterology,QiLu Hospital,Shandong University Jinan Shandong China 250012

Sponsors and Collaborators

  • Shandong University

Investigators

  • Study Chair: Li Yanqing, PhD, Qilu Hospital, Shandong University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yanqing Li, Vice president of QiLu Hospital, Shandong University
ClinicalTrials.gov Identifier:
NCT04956679
Other Study ID Numbers:
  • 2019SDU-QILU-186
First Posted:
Jul 9, 2021
Last Update Posted:
Oct 12, 2021
Last Verified:
Oct 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yanqing Li, Vice president of QiLu Hospital, Shandong University

Study Results

No Results Posted as of Oct 12, 2021